Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-aα deficiency

Roberta Resaz, Cristina Vanni, Daniela Segalerba, Angela R. Sementa, Luca Mastracci, Federica Grillo, Daniele Murgia, Maria Carla Bosco, Janice Y. Chou, Ottavia Barbieri, Luigi Varesio, Alessandra Eva

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Glycogen storage disease type 1a (GSD-1a) is caused by a deficiency in glucose-6-phosphatase-aα (G6Pase-aα), and is characterized by impaired glucose homeostasis and a high risk of developing hepatocellular adenomas (HCAs). A globally G6Pase-aα- deficient (G6pc-/-) mouse model that shows pathological features similar to those of humans with GSD-1a has been developed. These mice show a very severe phenotype of disturbed glucose homeostasis and rarely live beyond weaning. We generated liverspecific G6Pase-aα-deficient (LS-G6pc-/-) mice as an alternative animal model for studying the long-term pathophysiology of the liver and the potential treatment strategies, such as cell therapy. LSG6pc-/-mice were viable and exhibited normal glucose profiles in the fed state, but showed significantly lower blood glucose levels than their control littermates after 6 hours of fasting. LS-G6pc-/-mice developed hepatomegaly with glycogen accumulation and hepatic steatosis, and progressive hepatic degeneration. Ninety percent of the mice analyzed developed amyloidosis by 12 months of age. Finally, 25% of the mice sacrificed at age 10-20 months showed the presence of multiple HCAs and in one case late development of hepatocellular carcinoma (HCC). In conclusion, LS-G6pc-/-mice manifest hepatic symptoms similar to those of human GSD-1a and, therefore, represent a valid model to evaluate long-term liver pathogenesis of GSD-1a.

Original languageEnglish
Pages (from-to)1083-1091
Number of pages9
JournalDMM Disease Models and Mechanisms
Volume7
Issue number9
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Glycogen Storage Disease Type I
Liver Cell Adenoma
Glucose-6-Phosphatase
Glycogen
Liver
Hepatocellular Carcinoma
Glycogen Storage Disease
Glucose
Liver Glycogen
Homeostasis
Blood Glucose
Animals
Hepatomegaly
Amyloidosis
Cell- and Tissue-Based Therapy
Weaning
Fasting
Animal Models
Phenotype

Keywords

  • Animal model
  • Glucose-6-phosphatase-aα
  • Glycogen storage disease type 1a
  • Hepatic steatosis
  • Hepatocellular adenoma
  • Hepatocellular carcinoma
  • Hepatomegaly

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)
  • Medicine(all)

Cite this

Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-aα deficiency. / Resaz, Roberta; Vanni, Cristina; Segalerba, Daniela; Sementa, Angela R.; Mastracci, Luca; Grillo, Federica; Murgia, Daniele; Bosco, Maria Carla; Chou, Janice Y.; Barbieri, Ottavia; Varesio, Luigi; Eva, Alessandra.

In: DMM Disease Models and Mechanisms, Vol. 7, No. 9, 01.09.2014, p. 1083-1091.

Research output: Contribution to journalArticle

@article{ef26e9823fe84e6a9dcce061cdd68874,
title = "Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-aα deficiency",
abstract = "Glycogen storage disease type 1a (GSD-1a) is caused by a deficiency in glucose-6-phosphatase-aα (G6Pase-aα), and is characterized by impaired glucose homeostasis and a high risk of developing hepatocellular adenomas (HCAs). A globally G6Pase-aα- deficient (G6pc-/-) mouse model that shows pathological features similar to those of humans with GSD-1a has been developed. These mice show a very severe phenotype of disturbed glucose homeostasis and rarely live beyond weaning. We generated liverspecific G6Pase-aα-deficient (LS-G6pc-/-) mice as an alternative animal model for studying the long-term pathophysiology of the liver and the potential treatment strategies, such as cell therapy. LSG6pc-/-mice were viable and exhibited normal glucose profiles in the fed state, but showed significantly lower blood glucose levels than their control littermates after 6 hours of fasting. LS-G6pc-/-mice developed hepatomegaly with glycogen accumulation and hepatic steatosis, and progressive hepatic degeneration. Ninety percent of the mice analyzed developed amyloidosis by 12 months of age. Finally, 25{\%} of the mice sacrificed at age 10-20 months showed the presence of multiple HCAs and in one case late development of hepatocellular carcinoma (HCC). In conclusion, LS-G6pc-/-mice manifest hepatic symptoms similar to those of human GSD-1a and, therefore, represent a valid model to evaluate long-term liver pathogenesis of GSD-1a.",
keywords = "Animal model, Glucose-6-phosphatase-aα, Glycogen storage disease type 1a, Hepatic steatosis, Hepatocellular adenoma, Hepatocellular carcinoma, Hepatomegaly",
author = "Roberta Resaz and Cristina Vanni and Daniela Segalerba and Sementa, {Angela R.} and Luca Mastracci and Federica Grillo and Daniele Murgia and Bosco, {Maria Carla} and Chou, {Janice Y.} and Ottavia Barbieri and Luigi Varesio and Alessandra Eva",
year = "2014",
month = "9",
day = "1",
doi = "10.1242/dmm.014878",
language = "English",
volume = "7",
pages = "1083--1091",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "9",

}

TY - JOUR

T1 - Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-aα deficiency

AU - Resaz, Roberta

AU - Vanni, Cristina

AU - Segalerba, Daniela

AU - Sementa, Angela R.

AU - Mastracci, Luca

AU - Grillo, Federica

AU - Murgia, Daniele

AU - Bosco, Maria Carla

AU - Chou, Janice Y.

AU - Barbieri, Ottavia

AU - Varesio, Luigi

AU - Eva, Alessandra

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Glycogen storage disease type 1a (GSD-1a) is caused by a deficiency in glucose-6-phosphatase-aα (G6Pase-aα), and is characterized by impaired glucose homeostasis and a high risk of developing hepatocellular adenomas (HCAs). A globally G6Pase-aα- deficient (G6pc-/-) mouse model that shows pathological features similar to those of humans with GSD-1a has been developed. These mice show a very severe phenotype of disturbed glucose homeostasis and rarely live beyond weaning. We generated liverspecific G6Pase-aα-deficient (LS-G6pc-/-) mice as an alternative animal model for studying the long-term pathophysiology of the liver and the potential treatment strategies, such as cell therapy. LSG6pc-/-mice were viable and exhibited normal glucose profiles in the fed state, but showed significantly lower blood glucose levels than their control littermates after 6 hours of fasting. LS-G6pc-/-mice developed hepatomegaly with glycogen accumulation and hepatic steatosis, and progressive hepatic degeneration. Ninety percent of the mice analyzed developed amyloidosis by 12 months of age. Finally, 25% of the mice sacrificed at age 10-20 months showed the presence of multiple HCAs and in one case late development of hepatocellular carcinoma (HCC). In conclusion, LS-G6pc-/-mice manifest hepatic symptoms similar to those of human GSD-1a and, therefore, represent a valid model to evaluate long-term liver pathogenesis of GSD-1a.

AB - Glycogen storage disease type 1a (GSD-1a) is caused by a deficiency in glucose-6-phosphatase-aα (G6Pase-aα), and is characterized by impaired glucose homeostasis and a high risk of developing hepatocellular adenomas (HCAs). A globally G6Pase-aα- deficient (G6pc-/-) mouse model that shows pathological features similar to those of humans with GSD-1a has been developed. These mice show a very severe phenotype of disturbed glucose homeostasis and rarely live beyond weaning. We generated liverspecific G6Pase-aα-deficient (LS-G6pc-/-) mice as an alternative animal model for studying the long-term pathophysiology of the liver and the potential treatment strategies, such as cell therapy. LSG6pc-/-mice were viable and exhibited normal glucose profiles in the fed state, but showed significantly lower blood glucose levels than their control littermates after 6 hours of fasting. LS-G6pc-/-mice developed hepatomegaly with glycogen accumulation and hepatic steatosis, and progressive hepatic degeneration. Ninety percent of the mice analyzed developed amyloidosis by 12 months of age. Finally, 25% of the mice sacrificed at age 10-20 months showed the presence of multiple HCAs and in one case late development of hepatocellular carcinoma (HCC). In conclusion, LS-G6pc-/-mice manifest hepatic symptoms similar to those of human GSD-1a and, therefore, represent a valid model to evaluate long-term liver pathogenesis of GSD-1a.

KW - Animal model

KW - Glucose-6-phosphatase-aα

KW - Glycogen storage disease type 1a

KW - Hepatic steatosis

KW - Hepatocellular adenoma

KW - Hepatocellular carcinoma

KW - Hepatomegaly

UR - http://www.scopus.com/inward/record.url?scp=84907187456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907187456&partnerID=8YFLogxK

U2 - 10.1242/dmm.014878

DO - 10.1242/dmm.014878

M3 - Article

C2 - 25147298

AN - SCOPUS:84907187456

VL - 7

SP - 1083

EP - 1091

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 9

ER -